

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

|                       |                              |
|-----------------------|------------------------------|
| SUBMISSION TYPE:      | NEW ASSIGNMENT               |
| NATURE OF CONVEYANCE: | Release of Security Interest |

|                                     |                 |                       |                               |
|-------------------------------------|-----------------|-----------------------|-------------------------------|
| <b>CONVEYING PARTY DATA</b>         |                 |                       |                               |
| <b>Name</b>                         | <b>Formerly</b> | <b>Execution Date</b> | <b>Entity Type</b>            |
| The Bay City Capital Fund III, L.P. |                 | 12/23/2003            | LIMITED PARTNERSHIP: DELAWARE |

|                             |                                     |
|-----------------------------|-------------------------------------|
| <b>RECEIVING PARTY DATA</b> |                                     |
| <b>Name:</b>                | Reliant Pharmaceuticals, LLC        |
| <b>Street Address:</b>      | 110 Allen Road                      |
| <b>City:</b>                | Liberty Corner                      |
| <b>State/Country:</b>       | NEW JERSEY                          |
| <b>Postal Code:</b>         | 07938                               |
| <b>Entity Type:</b>         | Limited Liability Company: DELAWARE |

**PROPERTY NUMBERS Total: 17**

| Property Type        | Number   | Word Mark               |
|----------------------|----------|-------------------------|
| Serial Number:       | 78172324 | INNOPRAN XL             |
| Serial Number:       | 78169931 | INPRAN XL               |
| Serial Number:       | 78169911 | INNPRAN XL              |
| Serial Number:       | 78113058 | BETADUR                 |
| Serial Number:       | 78111782 | AXISUR                  |
| Serial Number:       | 78111770 | SUPRESID                |
| Registration Number: | 2551682  | RELIANT PHARMACEUTICALS |
| Registration Number: | 2669624  | RELIANT PHARMACEUTICALS |
| Registration Number: | 2664070  | R                       |
| Registration Number: | 2481169  |                         |
| Registration Number: | 1413953  | DYNACIRC                |
| Registration Number: | 1480436  |                         |
| Registration Number: | 1504573  | DYNACIRC                |
| Registration Number: | 1687539  | DYNACIRC CR             |

OP \$440.00 78172324

|                      |         |                  |
|----------------------|---------|------------------|
| Registration Number: | 1415563 | AXID             |
| Registration Number: | 2028868 | LIVING WITH GERD |
| Registration Number: | 2030167 | LIVING WITH GERD |

**CORRESPONDENCE DATA**

Fax Number: (312)993-9767  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: (312) 876-7700  
Email: matthew.walch@lw.com  
Correspondent Name: Matthew W. Walch  
Address Line 1: 233 S. Wacker Dr., Suite 5800  
Address Line 4: Chicago, ILLINOIS 60606

|                         |             |
|-------------------------|-------------|
| ATTORNEY DOCKET NUMBER: | 029203-0020 |
|-------------------------|-------------|

|                    |                    |
|--------------------|--------------------|
| NAME OF SUBMITTER: | Thomas J. Buettner |
|--------------------|--------------------|

**Total Attachments: 3**  
source=Release of Security Interest#page1.tif  
source=Release of Security Interest#page2.tif  
source=Release of Security Interest#page3.tif

## RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of December 23, 2003 (this "**Release**"), is executed by The Bay City Capital Fund III, L.P., a Delaware limited partnership in its capacity as collateral agent ("**Collateral Agent**"), in favor of Reliant Pharmaceuticals, LLC, a Delaware limited liability company ("**Borrower**"). Capitalized terms used herein, but not otherwise defined, shall have the meaning ascribed to them in the Credit Agreement, dated as of November 13, 2002 (as amended, the "**Credit Agreement**"), among Borrower and the lenders identified therein (the "**Lenders**").

WHEREAS, pursuant to that certain Amended and Restated Collateral Agency Agreement, dated as of November 13, 2002, the Collateral Agent has been appointed as the collateral agent for the Lenders;

WHEREAS, Collateral Agent and Borrower are parties to that certain Amended and Restated Trademark Security Agreement, dated as of November 13, 2002, and that certain Supplemental Trademark Security Agreement, dated as of March 11, 2003 (collectively, the "**Trademark Security Agreement**");

WHEREAS, the Trademark Security Agreement granted the Collateral Agent, for the ratable benefit of the Lenders, a first priority security interest in, among other things, the Trademark Collateral (as defined in the Trademark Security Agreement), which included, without limitation, the trademarks listed on Schedule A attached hereto as security for certain obligations of Borrower to the Lenders (the "**Obligations**");

WHEREAS, Collateral Agent recorded the Trademark Security Agreement on April 30, 2003 at Reel 2722, Frame 0323 in the United States Patent and Trademark Office; and

WHEREAS, pursuant to that certain Agreement Relating to Credit Documents, dated as of December 23, 2003, among Borrower and the Lenders, Borrower has satisfied all of the Obligations and Collateral Agent has agreed to release its security interests in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

1. Termination and Release of Liens. Collateral Agent hereby fully releases and terminates its security interests in and liens in all of Borrower's right, title and interest in, to and under the Trademark Collateral, including, without limitation:

(a) all of Borrower's now existing or hereafter acquired right, title and interest in and to: all trademarks which are now filed with the U.S. Patent and Trademark Office, any similar office or agency of any state, territory or possession of the United States or Canada or any similar office or agency of any other country or used in the United States, any state, territory or possession thereof including, without limitation, Puerto Rico, or any other country, and (i) any renewals thereof, (ii) all income, royalties, damages and payments now and hereafter due or payable with respect thereto, including, without limitation, payments under all

(b) any and all of the proceeds of any of the foregoing, including, without limitation, any claims by Borrower against third parties for infringement of the Patent Collateral or of any license with respect thereto.


2. Further Assurances. Collateral Agent further agrees, at the sole cost and expense of Borrower, to perform all necessary acts to affect the release and termination of its security interests and liens in the Patent Collateral, including, but not limited to the recording, filing and entering into any agreements, documents, forms or papers needed to accomplish such release and termination.

3. Governing Law. This Release shall be governed by and construed in accordance with the laws of the State of New York, without regard to the principles of conflicts of laws of such state (other than Sections 5-1401 and 5-1402 of the General Obligations Law of the State of New York).

IN WITNESS WHEREOF, Collateral Agent has caused this Release to be duly executed and delivered as of the day and year first above written.

**THE BAY CITY CAPITAL FUND III, L.P., as  
Collateral Agent**

By: Bay City Capital Management III, LLC  
Its: General Partner

By:   
Name:  
Title:

**RELEASE OF SECURITY INTEREST IN TRADEMARKS**

**SCHEDULE A**

**TRADEMARK REGISTRATIONS**

| <b><u>Mark</u></b>            | <b><u>Registration Number</u></b> | <b><u>Registration Date</u></b> |
|-------------------------------|-----------------------------------|---------------------------------|
| RELIANT PHARMACEUTICALS       | 2551682                           | March 26, 2002                  |
| RELIANT PHARMACEUTICALS       | 2669624                           | December 31, 2002               |
| R (and Design)                | 2664070                           | December 17, 2002               |
| (Design only)                 | 2481169                           | August 28, 2001                 |
| DYNACIRC                      | 1413953                           | October 21, 1986                |
| (Design only)                 | 1480436                           | March 15, 1988                  |
| DYNACIRC (Stylized)           | 1504573                           | September 20, 1988              |
| DYNACIRC CR                   | 1687539                           | May 19, 1992                    |
| AXID                          | 1415563                           | November 4, 1986                |
| LIVING WITH GERD              | 2028868                           | January 7, 1997                 |
| LIVING WITH GERD (and Design) | 2030167                           | January 14, 1997                |

**TRADEMARK APPLICATIONS**

| <b><u>Mark</u></b> | <b><u>Serial Number</u></b> | <b><u>Filing Date</u></b> |
|--------------------|-----------------------------|---------------------------|
| INNOPRAN XL        | 78/172,324                  | October 8, 2002           |
| INPRAN XL          | 78/169,931                  | October 1, 2002           |
| INNPRAN XL         | 78/169,911                  | October 1, 2002           |
| BETADUR            | 78/113,058                  | March 6, 2002             |
| AXISUR             | 78/111,782                  | February 28, 2002         |
| SUPRESID           | 78/111,770                  | February 28, 2002         |